Table: Sawai Pharmaceutical -9-MTH group results (IFRS)

SAWAI group

14/02/2019 06:00

Feb 14 (Reuters)- 
              Sawai Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2018        Dec 31, 2017     Mar 31, 2019 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              138.00              127.20           172.50    
                   (+8.5 pct)                           (+2.6 pct)  
  Operating           21.90               20.91            24.00    
                   (+4.8 pct)                           (+8.1 pct)  
  Pretax              21.83               21.28            23.70    
                   (+2.6 pct)                           (+17.0 pct) 
  Net                 16.80               15.64            17.40    
                   (+7.4 pct)                           (+24.1 pct) 
  EPS Basic        383.87 yen          419.93 yen       397.49 yen  
  EPS Diluted      383.62 yen          419.66 yen                   
  Ann Div                              130.00 yen       130.00 yen  
  -Q2 Div           65.00 yen           65.00 yen                   
  -Q4 Div                               65.00 yen        65.00 yen  
 
  NOTE - Sawai Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4555.T